First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours

NCT05759923 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Ovarian Carcinoma
Advanced Renal Cell Carcinoma
Advanced Pancreatic Carcinoma
Advanced Colorectal Carcinoma
Metastatic Pancreatic Carcinoma
Metastatic Colorectal Carcinoma
Metastatic Renal Cell Carcinoma
Metastatic Ovarian Carcinoma

Interventions

DRUG: OATD-02

Sponsor

Molecure S.A.